Looking at the universe of stocks we cover at Dividend Channel, on 2/13/14, Columbia Seligman Premium Tech G (STK) will trade ex-dividend, for its quarterly dividend of $0.4625, payable on 2/26/14. As a percentage of STK's recent stock price of $15.57, this dividend works out to approximately 2.97%, so look for shares of Columbia Seligman Premium Tech G to trade 2.97% lower — all else being equal — when STK shares open for trading on 2/13/14.Below is a dividend history chart for STK, showing historical dividends prior to the most recent $0.4625 declared by Columbia Seligman Premium Tech G: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from STK is likely to continue, and whether the current estimated yield of 11.88% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of STK shares, versus its 200 day moving average: Looking at the chart above, STK's low point in its 52 week range is $13.77 per share, with $16.41 as the 52 week high point — that compares with a last trade of $15.52. In Tuesday trading, Columbia Seligman Premium Tech G shares are currently off about 0.5% on the day.
HOST // Robert Powell
Retirement Planning Event
More from Stocks
Netflix: 3 Key Reasons Investors Should Avoid Its High-Priced Stock
The streaming media giant faces much stiffer competition later this year and is very richly-valued.
Boeing Resumes Slide After Ethiopia Crash Probe Finds Lion Air 'Similarities'
Boeing shares extend declines Monday after investigators in Ethiopia said tjeir probe into last week's deadly cash of the planemaker's 737 MAX 8 jet found "clear similarities" to the October crash of a Lion Air plane that killed 189 people.
Marriott Sees $11 Billion in Shareholder Returns Under 3-Year Business Plan
Marriott International will look to return as much as $11 billion to shareholders over the next three years under a new business plan that includes nearly 300,000 new rooms, the company said Monday ahead of its annual investor presentation in New York.
Dermira Shares Rocket After Successful Phase II Eczema Treatment Study
Dermira shares doubled Monday after the group said its new eczema treatment passed a key study in adult patients with moderate-to-severe atopic dermatitis.